The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Understanding and Overcoming Major Barriers in Cancer Nanomedicine
Open accessAbstract
Cancer nanomedicine is currently under intense development for applications in cancer imaging, molecular diagnosis and targeted therapy [1–6]. The basic rationale is that nanometer-sized particles, such as quantum dots (QDs), colloidal gold and polymeric nanomicelles, have functional and structural properties that are not available from either discrete molecules or bulk materials [7–10]. When conjugated with targeting ligands such as monoclonal antibodies, peptides or small molecules, these nanoparticles can be used to target malignant tumor cells and the tumor microenvironment (e.g., tumor stroma and tumor vasculatures) with high specificity and affinity. In the ‘mesoscopic’ size range of 10 to 100 nm, nanoparticles also have large surface areas for conjugating to multiple diagnostic and therapeutic agents, opening up new possibilities in integrated cancer imaging and therapy. However, at present there are several fundamental problems and technical barriers that must be understood and overcome. These problems include nanoparticle surface opsonization (surface ‘fouling’ by nonspecific protein adsorption) [11–13], nanoparticle uptake and retention in reticuloendothelial organs (e.g., liver and spleen [14,15], difficulties in nanoparticle targeting and penetration in solid tumors [16,17], and the long-term fate and toxicity concerns of nanoparticles, especially nonbiodegradable nanomaterials containing toxic elements [18–20]. Thus, there is an urgent need to study these problems and to develop innovative strategies for overcoming them. In this article, we briefly discuss the major challenges and opportunities in developing cancer nanomedicine for molecular imaging, in vitro diagnostics and targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,772
Self-citationCancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281
The use of nanocrystals in biological detection
Alivisatos, P. (2004) · Nature Biotechnology · doi:10.1038/nbt927 · Cited by 3,008
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
A review of NIR dyes in cancer targeting and imaging
Luo, S., Zhang, E., Su, Y., Cheng, T., & Shi, C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.024 · Cited by 1,432
Gold Nanomaterials at Work in Biomedicine
Yang, X., Yang, M., Pang, B., Vara, M., & Xia, Y. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00193 · Cited by 1,162
Metadata
- Authors
- Nie, S.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2010-06
- Volume
- 5
- Issue
- 4
- Pages
- 523-528
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2157770632
- Cited by
- 498
- References
- 53
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding and Overcoming Major Barriers in Cancer Nanomedicine. https://app.cochat.ai/papers/10.2217/nnm.10.23
- The paper
- Nie, S. (2010). Understanding and Overcoming Major Barriers in Cancer Nanomedicine. Nanomedicine. https://doi.org/10.2217/nnm.10.23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.